Open house contracts for various active ingredients until 31.05.2025.
Adefovir dipivoxil, ATC-Code: J05AF08The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Etravirin, ATC-Code: J05AG04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Formoterol-Glycopyrroniumbromid-Beclometason, ATC-Code: R03AL09The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Fosamprenavir, ATC-Code: J05AE07The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Fulvestrant, ATC-Code: L02BA03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Gräserpollen, ATC-Code: V01AA02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Hausstaubmilben, ATC-Code: V01AA03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Ibuprofen, ATC-Code: M01AE01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Immunoglobulins, normal human, for intravascular use, ATC code: J06BA02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Infliximab, ATC-Code: L04AB02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.04.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Insect allergens, ATC code: V01AA07The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Baumpollen, ATC-Code: V01AA05The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Isosorbiddinitrat, ATC-Code: C01DA08The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Lamivudin, Abacavir und Dolutegravir, ATC-Code: J05AR13The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Lopinavir/Ritonavir, ATC-Code: J05AR10The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Macrogol, ATC-Code: A06AD15The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Macrogol, Kombinationen, ATC-Code: A06AD65The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Mebeverin, ATC-Code: A03AA04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Metoclopramid, ATC-Code: A03FA01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Metoprolol-Hydrochlorothazid, ATC-Code: C07BB22The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Multienzyme - Pankreatin (Lipase, Protease etc.), ATC-Code: A09AA02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Natriumhydrogencarbonat, ATC-Code: A02AH01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Calciumcarbonat/Colecalciferol, ATC-Code: A12AX01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Pirfenidone, ATC code: L04AX05The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Risperidon, ATC-Code: N05AX08The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Ritonavir, ATC-Code: J05AE03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Sulfasalazin, ATC-Code: M01CX02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Sultamicillin, ATC-Code: J01CR04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Tamsulosin und Dutasterid, ATC-Code: G04CA52The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Tobramycin, ATC-Code: J01GB01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Valproinsäure, ATC-Code: N03AG01The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Various allergen extracts, ATC code: V01AA20The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Vilanterol und Fluticasonfuroat, ATC-Code: R03AK10The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.04.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Chlortalidon, ATC-Code: C03BA04The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Colecalciferol (Vit. D3), ATC-Code: A11CC05The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Dasatinib, ATC-Code: L01EA02The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.04.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Dolutegravir, ATC-Code: J05AJ03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Emtricitabin+Tenofovirdisoproxil+Rilpivirin, ATC-Code: J05AR08The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.04.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.
Erlotinib, ATC-Code: L01XE03The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for various active substances in the context of a so-called open-house procedure. Under the specification of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be able to conclude or join a
Discount agreement according to § 130a Abs. 8 SGB V for the mentioned active ingredient offered. The earliest contract start is 01.06.2023, contract end is 31.05.2025. Joining this open-house procedure is possible at any time during the term of the contract.